Liu Fengqin, Miao Xia, Han Lu, Song Xiao
The Third Department of Geriatrics, Weifang People's Hospital, Weifang, Shandong, China.
Central Supply Service Department (CSSD), Weifang People's Hospital, Weifang, Shandong, China.
Front Oncol. 2024 May 28;14:1390006. doi: 10.3389/fonc.2024.1390006. eCollection 2024.
Lung cancer remains one of the leading causes of cancer-related mortality worldwide necessitating the development of innovative therapeutic strategies. Chimeric antigen receptor (CAR) natural killer (NK) cell therapy represents a promising advancement in the field of oncology offering a novel approach to target and eliminate tumor cells with high specificity and reduced risk of immune-related adverse effects. This paper reviews the mechanism, potential targets, and recent advances in CAR-NK cell therapy for lung cancer, including the design and engineering of CAR-NK cells, preclinical studies, and the outcomes of early-phase clinical trials. We highlight the unique advantages of using NK cells, such as their innate ability to recognize and kill cancer cells and their reduced potential for inducing graft-versus-host disease (GvHD) and cytokine release syndrome (CRS) compared to CAR T-cell therapies. Results from recent studies demonstrate significant antitumor activity in lung cancer models with improved targeting and persistence of CAR-NK cells observed and . Finally, we discuss the challenges in optimizing CAR-NK cell therapies, including the potential resistance mechanisms. The paper concludes with an outlook on the future directions of CAR-NK cell research and its implications for lung cancer treatment emphasizing the importance of continued innovation and collaboration in the field.
肺癌仍然是全球癌症相关死亡的主要原因之一，因此需要开发创新的治疗策略。嵌合抗原受体（CAR）自然杀伤（NK）细胞疗法是肿瘤学领域一项有前景的进展，为靶向和消除肿瘤细胞提供了一种新方法，具有高特异性且免疫相关不良反应风险降低。本文综述了CAR-NK细胞疗法治疗肺癌的机制、潜在靶点和最新进展，包括CAR-NK细胞的设计与工程、临床前研究以及早期临床试验的结果。我们强调了使用NK细胞的独特优势，例如它们识别和杀死癌细胞的固有能力，以及与CAR T细胞疗法相比，其引发移植物抗宿主病（GvHD）和细胞因子释放综合征（CRS）的可能性更低。近期研究结果表明，在肺癌模型中CAR-NK细胞具有显著的抗肿瘤活性，观察到其靶向性和持久性有所改善。最后，我们讨论了优化CAR-NK细胞疗法面临的挑战，包括潜在的耐药机制。本文最后展望了CAR-NK细胞研究的未来方向及其对肺癌治疗的意义，强调了该领域持续创新与合作的重要性。
